GlassScriptPhysician profile
Vivek Mehta
NPI 1629085782
$1,515.62
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $14.51 · 2021: $114 · 2022: $115 · 2023: $151 · 2024: $686 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $598.34 | 2024-2025 | Eterna, Perclose Prostyle, Proclaim |
| Teva Pharmaceuticals USA, INC. | $260.19 | 2021-2024 | Ajovy, Austedo Xr |
| Medtronic USA, INC. | $142.10 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.08 | 2019 | |
| Spr Therapeutics, INC | $72.24 | 2024 | Sprint Pns System |
| Medtronic, INC. | $71.84 | 2023-2024 | Vanta Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $50.00 | 2021 | |
| Biogen, INC. | $47.73 | 2021-2023 | Spinraza |
| Pfizer INC. | $29.47 | 2019 | |
| Collegium Pharmaceutical, INC. | $29.38 | 2019-2023 | Belbuca |
| Si-Bone, INC. | $24.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2024 | Iqirvo |
| Novartis Pharmaceuticals Corporation | $20.67 | 2019 | |
| Boston Scientific Corporation | $18.21 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.40 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.92 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.67 | 2023 | Iovera, Exparel, Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.